Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin % Related Terms
ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin % Chart
ImmuneOnco Biopharmaceuticals (Shanghai) Annual Data
Trend
Dec21
Dec22
Dec23
Dec24
Dec25
Net Margin %
-14,466.02
-74,861.56
-98,351.66
-425.97
-141.67
ImmuneOnco Biopharmaceuticals (Shanghai) Semi-Annual Data
HKSE:01541 vs VRTX, REGN, RVMD: Net Margin % Comparison
For the Biotechnology subindustry, ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ImmuneOnco Biopharmaceuticals (Shanghai) Net Margin % vs Biotechnology Industry
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a Net Margin % of -56.76% as of Dec. 2025. Net margin is the ratio of total net income to net sales. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. According to the industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #527 out of 944 companies in the Biotechnology industry, placing it in the top 55.8%.
Is ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin % too high?
ImmuneOnco Biopharmaceuticals (Shanghai)'s current Net Margin % is -56.76%. Based on the distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #527 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, ImmuneOnco Biopharmaceuticals (Shanghai) has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does ImmuneOnco Biopharmaceuticals (Shanghai)'s Net Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, ImmuneOnco Biopharmaceuticals (Shanghai) ranks #527 out of 944 companies for Net Margin %. This places ImmuneOnco Biopharmaceuticals (Shanghai) in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Biotechnology company?
A good Net Margin % depends on the Biotechnology industry context. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on ImmuneOnco Biopharmaceuticals (Shanghai) and its competitors. ImmuneOnco Biopharmaceuticals (Shanghai)'s current Net Margin % is -56.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ImmuneOnco Biopharmaceuticals (Shanghai) stock overvalued right now?
ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541) has a current Net Margin % of -56.76%. The current Net Margin % is -56.76%. ImmuneOnco Biopharmaceuticals (Shanghai)'s overall GF Score™ is 6/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For ImmuneOnco Biopharmaceuticals (Shanghai) (HKSE:01541), the current Net Margin % is -56.76% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
ImmuneOnco Biopharmaceuticals (Shanghai) Inc is a science-driven biotechnology company dedicated to the development of immuno-oncology therapies. It is one of the few biotechnology companies globally adopting a systematic approach to harness both the innate and adaptive immune systems. It has designed a robust pipeline of over ten drug candidates with 12 ongoing clinical programs., featured by a comprehensive innate-immunity-based asset portfolio. Its pipeline reflects its extensive understanding of the frontiers of cancer biology and immunology and its expertise in turning scientific research into drug candidates.
6GF Score
Get the complete analysis for HKSE:01541
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01541 has been successfully added to your 
